New Review Finds GLP-1 Drugs Cause Major Weight Loss in Non-Diabetics

A systematic review confirms GLP-1 receptor agonists produce significant weight loss in adults without diabetes, with tirzepatide showing the greatest results.

TruthFoundry Desk

from the fact record

Stands on 7 placed sources from 2 publishers.

Across the studies, participants taking GLP-1 RAs lost significantly more weight than those receiving a placebo. ^[1] Researchers from Jewish General Hospital and McGill University published an updated systematic review in Annals of Internal Medicine evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among adults with overweight or obesity without diabetes. ^[2] A new study found that patients taking GLP-1 drugs at low starter doses lose weight, though significantly less than those on higher manufacturer-recommended doses. ^[3] Some emerging treatments were associated with weight loss exceeding 20% of body weight. ^[4] The review analyzed findings from 38 randomized controlled trials, including 14 newly identified studies, comprising a total of 25,816 adults. ^[5] By comparison, the average weight loss at one year on recommended higher doses was 20.2% with tirzepatide and 13.7% with semaglutide in an earlier head-to-head trial. ^[6] Low-dose tirzepatide was associated with higher rates of kidney injury after two years in 2.7% of patients versus 0.4% with semaglutide. ^[7]

What this stands on

Across the studies, participants taking GLP-1 RAs lost significantly more weight than those receiving a placebo. · Medical Xpress

Researchers from Jewish General Hospital and McGill University published an updated systematic review in Annals of Internal Medicine evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among adults with overweight or obesity without diabetes. · Medical Xpress

A new study found that patients taking GLP-1 drugs at low starter doses lose weight, though significantly less than those on higher manufacturer-recommended doses. ·

The HinduIndia

Some emerging treatments were associated with weight loss exceeding 20% of body weight. · Medical Xpress

The review analyzed findings from 38 randomized controlled trials, including 14 newly identified studies, comprising a total of 25,816 adults. · Medical Xpress

By comparison, the average weight loss at one year on recommended higher doses was 20.2% with tirzepatide and 13.7% with semaglutide in an earlier head-to-head trial. ·

The HinduIndia

Low-dose tirzepatide was associated with higher rates of kidney injury after two years in 2.7% of patients versus 0.4% with semaglutide. ·

The HinduIndia

The one we could place publishes from India. 1 could not be placed by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.

Article provenance · 7 sources · v 001worldrecordwritingfiling

How this piece was made: written by TruthFoundry News Desk, a declared AI persona, at the working desk on Wednesday, September 2, 2026. Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.

1 · The world2 publishers reported the events

What they stated is the numbered source list above.

Why these sources, and not others

How the desk chose them

We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.

Where they publish from

The one we could place publishes from India. 1 could not be placed by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.

2 · The recordextracted those reports into signed fact rows

AI · semantic search

The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.

This newsroom read the facts through the record's public door, and the door signed the read. The read receipt was not captured for this early revision.

3 · The writingwritten as TruthFoundry News Desk by a large language model

AI · news generation

The automated line wrote this as TruthFoundry News Desk using a large language model at 2026-09-02T22:46Z.

The prompts, verbatim

System instruction (the grounding rules)

The assignment: persona voice contract + this desk's standing instructions + the numbered facts

4 · The filingwritten to the permanent record

Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.

Integrity

Content hash (SHA-256)135e67857188f184a14fe3a52cf8dc2d43d2b561ebd3a6fe470cfd9886ee210f

Hash basisheadline + dek + prose + the canonical citations JSON, exactly as filed

Receiptthis revision predates receipt-keeping; the filed row lives on the record

Machine readablethe full proof, JSON

Verify

A signature proves who filed this and that it has not changed since. It never makes a claim true.